Use of antidepressants in patients with moderate-to-severe Crohn's disease

被引：0
|
作者：
Lichtenstein, GR
Colombel, JF
Yan, S
Bala, M
Olson, A
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Hop Calmette, Lille, France
[3] Centocor Inc, Malvern, PA 19355 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2004年 / 99卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
773
引用
收藏
页码：S250 / S251
页数：2
相关论文
共 50 条
  • [21] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
    Morales Bermudez, A. I.
    Bravo Aranda, A. M.
    Martinez Burgos, M.
    Olmedo Martin, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
  • [22] COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS
    White, M. K.
    Yarlas, A.
    Ingham, M.
    Han, C.
    VALUE IN HEALTH, 2016, 19 (03) : A316 - A316
  • [23] Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn's disease: a pooled analysis
    Louis, E. J.
    Lofberg, R.
    Reinisch, W.
    Schwartz, D.
    Maa, J-F
    Berg, S.
    Huang, B.
    Wang, A. W.
    Robinson, A. M.
    Pappalardo, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S351 - S352
  • [24] Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease
    Tang, Derek H.
    Armstrong, Edward P.
    Lee, Jeannie K.
    PHARMACOTHERAPY, 2012, 32 (06): : 515 - 526
  • [25] Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
    Marehbian, Josh
    Arrighi, H. Michael
    Hass, Steve
    Tian, Haijun
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2524 - 2533
  • [26] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    Advances in Therapy, 2021, 38 : 4233 - 4245
  • [27] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [28] Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease
    Smith, Lisa S.
    Nelson, Michael
    Dolder, Christian R.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 333 - 342
  • [29] Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease
    Lusetti, Francesca
    D'Amico, Ferdinando
    Allocca, Mariangela
    Furfaro, Federica
    Zilli, Alessandra
    Fiorino, Gionata
    Parigi, Tommaso Lorenzo
    Radice, Simona
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    IMMUNOTHERAPY, 2024, 16 (09) : 581 - 595
  • [30] A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease
    Ahmed, Waseem
    Lukin, Dana J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12): : 973 - 975
12345